ストックスクリーナーアプリを入手
2.00
6.98%
-0.15
アフターアワーズ：
2.09
0.09
+4.50%
前日終値:
$2.15
開ける：
$2.18
24時間の取引高:
71,480
Relative Volume:
0.36
時価総額：
$15.98M
収益：
$2.85M
当期純損益:
$93.35M
株価収益率:
0.0831
EPS:
24.0802
ネットキャッシュフロー:
$-19.47M
1週間 パフォーマンス:
-0.99%
1か月 パフォーマンス:
+26.58%
6か月 パフォーマンス:
+6.38%
1年 パフォーマンス:
-24.53%
1日の値動き範囲:
$1.88
$2.18
1週間の範囲:
$1.88
$2.29
52週間の値動き範囲:
$0.97
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Compare TRAW vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.00 | 17.18M | 2.85M | 93.35M | -19.47M | 24.08 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | 開始されました | H.C. Wainwright | Buy |
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-18 | 開始されました | Guggenheim | Buy |
| 2018-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-09 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-27 | 開始されました | Laidlaw | Buy |
| 2015-07-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Traws Pharma Inc (TRAW) 最新ニュース
Published on: 2026-03-23 16:58:08 - baoquankhu1.vn
Traws Pharma (TRAW) Expected to Announce Earnings on Monday - Defense World
Aug Weekly: Whats the analyst consensus on Traws Pharma IncMarket Risk Analysis & High Win Rate Trade Tips - baoquankhu1.vn
Traws Pharma reports phase 2 COVID-19 data, flu program update - MSN
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones - MSN
Director at Traws Pharma (TRAW) receives grant of 33,435 stock options - Stock Titan
Traws Pharma (TRAW) director granted 31,258 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) director granted 33,435 stock options at $1.60 strike - Stock Titan
Traws Pharma (TRAW) awards CEO 231,336 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) awards 118,367 stock options to Chief Science Officer - Stock Titan
Traws Pharma (TRAW) COO receives grant of 96,899 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover - Stock Titan
Traws Pharma (TRAW) CMO awarded 108,854 stock options at $1.60 - Stock Titan
Traw Pharma director granted 33,435 stock options | TRAW SEC FilingForm 4 - Stock Titan
Will Traws Pharma Inc. (0T20) stock draw ESG focused fundsWeekly Profit Summary & High Accuracy Investment Signals - Naître et grandir
TRAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cash per share of Traws Pharma, Inc. – FWB:0T20 - TradingView
TRAW SEC FilingsTraws Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update - MyChesCo
Traws Pharma (NASDAQ:TRAW) Trading Down 11.2% – Here’s What Happened - Defense World
Insider Sell: How much upside does Traws Pharma Inc haveTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn
TRAWTraws Pharma Latest Stock News & Market Updates - Stock Titan
Traws Pharma Reports Differentiated COVID-19 and Influenza Antiviral Progress - Contagion Live
Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold By Investing.com - Investing.com South Africa
Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold - Investing.com
Traws Pharma Highlights Positive Ratutrelvir Phase 2 COVID-19 Data - TipRanks
Traws Pharma Stock Plunges As FDA Halts TXM IND - RTTNews
Traws Pharma completes Phase 2 ratutrelvir analysis; tivoxavir tablet shows 28-day influenza protection potential - TradingView
Traws Pharma completes analysis of ratutrelvir clinical study in Paxlovid®-eligible and ineligible Covid-19 patients - marketscreener.com
Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients - TradingView
Traws Pharma Reports Completed Clinical Results of Ratutrelvir Showing Differentiated Profile Compared to PAXLOVID® with Fewer Adverse Events and No Viral Rebounds - Quiver Quantitative
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewswire
Ayrton Capital LLC Reduces Stake in Traws Pharma Inc - GuruFocus
Squadron funds disclose 8.9% Traws Pharma (TRAW) ownership in 13G/A filing - Stock Titan
Traws Pharma advances antiviral pipeline with multiple regulatory submissions - MSN
TRAW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can Traws Pharma Inc. stock rebound after recent weaknessJuly 2025 Decliners & Technical Buy Zone Confirmations - mfd.ru
How rising interest rates impact Traws Pharma Inc. stockMarket Volume Summary & Free Technical Confirmation Trade Alerts - mfd.ru
Aug EndMonth: Will RSVR outperform tech stocks2025 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
Why Traws Pharma Inc. stock could benefit from AI revolution - mfd.ru
Published on: 2026-02-03 21:55:07 - baoquankhu1.vn
LADENBURG THALM/SH SH Upgrades Traws Pharma (NASDAQ:TRAW) to Strong-Buy - Defense World
TRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment? - MSN
Traws completes enrollment in phase 2 COVID-19 drug study By Investing.com - Investing.com Canada
Traws Pharma stock soars after completing COVID-19 treatment study By Investing.com - Investing.com South Africa
Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com
TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? - Stocktwits
Traws Pharma (TRAW) Completes Enrollment in Phase 2 COVID-19 Stu - GuruFocus
Traws Pharma Completes Phase 2 Enrollment for COVID Candidate - TipRanks
Traws completes enrollment in phase 2 COVID-19 drug study - Investing.com
Traws Pharma Inc (TRAW) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):